LQDA Form 144: 82,477 Shares Sold in April

Serendipity Biopharma filed a Form 144 disclosing recent resale activity under 10b5-1 plans.

Rhea-AI Filing Summary

Serendipity Biopharma filed a Form 144 disclosing recent resale activity under 10b5-1 plans. The excerpt lists four sales: 3,300 shares on 04/14/2026 for $132,000; 32,744 shares on 04/13/2026 for $1,256,387.28; 21,433 shares on 04/10/2026 for $859,876.96; and 25,000 shares on 04/09/2026 for $1,002,887.50.

Insights

Securities Compliance Counsel

Routine Form 144 filings report planned resales, often under 10b5-1 plans.

The filing lists multiple dated resale transactions and identifies 10b5-1 sales as the method. These entries are procedural notifications required for certain officer/director/affiliate sales rather than new corporate actions.

Cash‑flow recipients and broader ownership context are not included in the excerpt; subsequent filings or broker disclosures would clarify any remaining holdings or aggregation of sales.

Key Figures

Sale on 04/13/2026: 32,744 shares / $1,256,387.28 Sale on 04/10/2026: 21,433 shares / $859,876.96 Sale on 04/09/2026: 25,000 shares / $1,002,887.50 +2 more

5 metrics

Sale on 04/13/2026 32,744 shares / $1,256,387.28 10b5-1 resale reported

Sale on 04/10/2026 21,433 shares / $859,876.96 10b5-1 resale reported

Sale on 04/09/2026 25,000 shares / $1,002,887.50 10b5-1 resale reported

Sale on 04/14/2026 3,300 shares / $132,000 10b5-1 resale reported

Total shares listed 82,477 shares Aggregate of listed sales in excerpt

Key Terms

Form 144, 10b5-1 sales, resale

3 terms

Form 144 regulatory

"144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

10b5-1 sales regulatory

"10b5-1 Sales for SERENDIPITY BIOPHARMA LLC"

10b5-1 sales are pre-arranged stock-trading plans that let company insiders automatically buy or sell shares according to a fixed schedule or formula, even if they later learn confidential information. Think of it as setting up an automatic thermostat for trades: it creates a clear, documented path that can protect insiders from insider-trading accusations and gives investors a signal about predictable insider activity—though it can also simply be a way for insiders to diversify or raise cash.

resale financial

"Securities To Be Sold"

Resale is the act of selling an item, asset, or security by someone who previously bought it rather than by the original maker or issuer. It matters to investors because resale activity affects how easily an investment can be sold, the price buyers are willing to pay, and the potential profit or loss — like selling a used car: condition, demand and market rules determine what you can get for it.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Serendipity Biopharma (LQDA) disclose in its Form 144?

The Form 144 lists four resale transactions by affiliates under 10b5-1 plans. It shows dated sales of 3,300; 32,744; 21,433; and 25,000 shares with corresponding gross proceeds for each listed in the filing excerpt.

Were the sales in the Form 144 executed under pre-arranged plans?

Yes. The excerpt explicitly identifies the transactions as 10b5-1 sales for Serendipity Biopharma. That indicates the resales were made under pre-established trading plans rather than necessarily being discretionary open-market trades by the reporting persons.

How much gross proceeds did the listed trades generate?

The excerpt reports gross proceeds of $132,000; $1,256,387.28; $859,876.96; and $1,002,887.50 for the respective sales on the listed dates. These amounts are the filing's reported transaction values for each sale entry.

Does the Form 144 excerpt state who received the sale proceeds?

No. The provided excerpt does not state who received the proceeds or how proceeds were used. It lists sale dates, share counts, and gross amounts but does not attribute cash flows to the issuer or selling holders in the visible text.

Do these Form 144 entries change Serendipity Biopharma’s capital structure?

The excerpt does not state any change to authorized or outstanding shares. Form 144s disclose intended resales by affiliates; they do not, by themselves, amend capital structure information in the provided text.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/15/2026 - 04:43 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001231615
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	LIQUIDIA CORPORATION
SEC File Number	001-39724
Address of Issuer	419 Davis Drive, Suite 100 Morrisville NORTH CAROLINA 27560
Phone	9193284400
Name of Person for Whose Account the Securities are To Be Sold	SERENDIPITY BIOPHARMA LLC
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	24733	957414.43	88114429	04/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/18/2020	Merger or Acquisition	Issuer			24733	11/18/2020	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100 Morrisville NC 27560	Common	04/14/2026	3300	132000.00
ROGER JEFFS 419 Davis Drive, Suite 100 Morrisville NC 27560	Common	04/13/2026	32744	1256387.28
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100 Morrisville NC 27560	Common	04/10/2026	21433	859876.96
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100 Morrisville NC 27560	Common	04/09/2026	25000	1002887.50

144: Remarks and Signature

Remarks
Date of Notice	04/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/05/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Roger Jeffs
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)